Beijing Weilin Hengchang Pharmaceutical Technology

Beijing Weilin Hengchang Pharmaceutical Technology is a China-based pharmaceutical R&D company specializing in the development of innovative small molecule drugs and high-end generic formulations. Established in 2014 and headquartered in Beijing, the company focuses on therapeutic areas including metabolic disorders, oncology, and cardiovascular diseases. Weilin Hengchang operates a comprehensive research platform that covers drug discovery, process chemistry, and clinical development. Its lead candidate, WLHC-1601, is a GPR40 agonist currently being evaluated for the treatment of type 2 diabetes. The company also provides contract research and technical services to the broader pharmaceutical industry, assisting with consistency evaluations and regulatory filings. Through its commitment to technical excellence, Weilin Hengchang aims to bridge the gap between laboratory research and commercial production to provide high-quality medical solutions.